Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature emphasizes perioperative neuroprotection and delirium prevention, with multiple randomized trials showing ketamine-class agents (S‑ketamine, esketamine) reduce postoperative neuropsychiatric complications or improve maternal outcomes. A notable chronotherapeutic signal emerged where sodium oxybate reduced delirium only for morning surgeries, suggesting time-of-day matters. Complementary advances include opioid‑sparing epidural strategies with downstream ment
Summary
This week’s anesthesiology literature emphasizes perioperative neuroprotection and delirium prevention, with multiple randomized trials showing ketamine-class agents (S‑ketamine, esketamine) reduce postoperative neuropsychiatric complications or improve maternal outcomes. A notable chronotherapeutic signal emerged where sodium oxybate reduced delirium only for morning surgeries, suggesting time-of-day matters. Complementary advances include opioid‑sparing epidural strategies with downstream mental‑health benefits and multiple mechanistic trials linking inflammation/endothelial protection to improved recovery.
Selected Articles
1. Subanesthetic S-ketamine prevents postoperative delirium and reduces inflammatory cytokines in older patients receiving hip fracture surgery: a randomized, controlled study.
In a randomized controlled trial of 356 older adults undergoing hip fracture surgery, subanesthetic S‑ketamine (0.3 mg/kg loading, 0.2 mg/kg/h infusion) reduced postoperative delirium from 29.8% to 9.6% within 7 days and improved sleep quality. It also suppressed proinflammatory cytokines (IL‑1β, IL‑6, TNF‑α) without changing early pain scores or opioid consumption, and reduced nausea/vomiting rates.
Impact: Provides high-quality randomized evidence that modulating neuroinflammation with subanesthetic S‑ketamine yields a large absolute reduction in postoperative delirium in a high‑risk surgical population.
Clinical Implications: Consider integrating subanesthetic S‑ketamine into multimodal delirium‑prevention protocols for older hip fracture patients, with monitoring for ketamine‑related effects and replication in other surgical settings.
Key Findings
- Postoperative delirium incidence reduced to 9.6% vs 29.8% within 7 days (P<0.001).
- Improved sleep quality (lower PSQI) from day of surgery through postoperative day 3 (P<0.001).
- Lower perioperative IL‑1β, IL‑6, and TNF‑α from D0 to D3 (P<0.01) and reduced nausea/vomiting (6.7% vs 28.1%).
- No difference in rest/movement pain scores through postoperative day 2 or in 48‑hour analgesic use.
2. Prophylactic effect of intraoperative sodium oxybate on postoperative delirium in older patients undergoing major orthopedic surgery: a randomized clinical trial.
In a double‑blind RCT of 332 older patients having spine or joint replacement surgery, intraoperative sodium oxybate did not reduce delirium overall but significantly lowered postoperative delirium incidence in morning surgeries (7.3% vs 18.5%; RR 0.395). No benefit was seen for afternoon surgeries, suggesting a time‑of‑day (chronotherapeutic) effect with acceptable safety.
Impact: One of the first randomized demonstrations of a time‑of‑day–dependent perioperative intervention effect on delirium, opening research and implementation pathways for chronotherapy in anesthesiology.
Clinical Implications: When considering pharmacologic delirium prevention, account for surgery timing; sodium oxybate may be considered for morning orthopedic cases where institutional workflows and contraindications allow, but broader adoption requires confirmatory multicenter trials.
Key Findings
- No overall POD reduction (10.3% vs 13.5%; P=0.372) in the full cohort.
- Significant POD reduction in morning surgeries (7.3% vs 18.5%; RR 0.395; P=0.033).
- No significant differences in safety, recovery metrics, pain, or sleep quality after multiplicity correction.
3. Esketamine as an opioid-sparing adjuvant for epidural labour analgesia: a randomised, double-blind trial evaluating postpartum depression.
In a randomized double‑blind trial of ~200 nulliparous parturients, esketamine (added to ropivacaine epidurals) shortened onset time, reduced ropivacaine consumption and maternal adverse events (pruritus, hypotension, urinary retention), and lowered EPDS scores at 42 days with reduced probable postpartum depression incidence compared to sufentanil‑containing epidurals.
Impact: Demonstrates an opioid‑sparing epidural adjuvant that improves immediate maternal safety and shows downstream benefit in postpartum depression scores — bridging analgesia with mental‑health outcomes.
Clinical Implications: Espketamine‑based epidural mixtures could replace opioid adjuvants in labor analgesia to speed onset and reduce maternal side effects and postpartum depression risk; multicenter confirmation and neonatal safety monitoring are advised prior to wide adoption.
Key Findings
- Faster onset of analgesia (5.9 vs 9.8 minutes) and higher T8 sensory block predominance.
- Lower ropivacaine consumption (≈17% reduction) and markedly fewer adverse events (pruritus, hypotension, urinary retention).
- Lower EPDS at 42 days and reduced probable postpartum depression incidence (4.0% vs 18.4%).